Updates

ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum

10/02/2019 Research

min. read

Topics

Read

Full media story at www.biospace.com

Related Stories

Research Aug 26, 2025

Study reveals how prolonged exposure to food orders can suppress appetites

Research Aug 25, 2025

Administering CAR T-cell therapy to younger patients requires ‘ongoing and open’ relationships

healio.com
Research Aug 21, 2025

2025 Cain Collaborative Pilot Grant Application Now Open

Research Aug 21, 2025

A Powerful New Tool to Solve Complex Diseases and Deliver Precision Medicine

Research Jul 07, 2025

Changes in the blood could protect against Alzheimer’s disease

Research Jul 01, 2025

New research points out a promising strategy for treating metastatic medulloblastoma

BCM.edu
See more results